Is PTC Therapeutics, Inc. (PTCT) halal? Doubtful. Based on AAOIFI screening, PTC Therapeutics, Inc. passes the business activity screen but has financial ratios approaching AAOIFI limits with a compliance score of 71/100 (Grade: B+).

PTC Therapeutics, Inc.

PTCT: Is PTC Therapeutics, Inc. Halal?

Doubtful

PTC Therapeutics, Inc.

NASDAQHealthcareUS

$68.23

-7.55%

About PTC Therapeutics, Inc.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Sector: Healthcare 路 Industry: Biotechnology

Why This Stock Is Doubtful

  • Interest-bearing deposits are 29.9% of market cap, only 0.1 points below the 30% limit

Stocks are marked Doubtful when financial ratios pass but approach AAOIFI thresholds. Consider consulting a qualified scholar for a definitive ruling.

Shariah Compliance Status

AAOIFI Standard 21Updated Jun 17, 2026
B+

Good

Good compliance with minor concerns

71Score

Business Activity Screen

Passed

Checks if the business is involved in prohibited activities (alcohol, gambling, pork, conventional banking, etc.)

Financial Ratio Screen

Passed

Financial ratios must be below AAOIFI thresholds

Debt / Market Cap4.4% / 30.0%

Compliance History

  1. Doubtfulnow

    since Jun 2026

  2. Not Halal

    until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Screened: Jun 17, 2026Fiscal: Q1 2026Source: EDGAR

Purify Your PTCT Dividends

Calculate your purification amount for PTCT dividends based on AAOIFI standards.

Financial Overview

Market Cap

5.7B

Price

$68.23

Sector

Healthcare

Industry

Biotechnology

More Healthcare Stocks

JNJ

Johnson & Johnson

A

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

A

PFE

Pfizer Inc.

F

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+
Free 路 No credit card required

Track PTCT and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started FreeBrowse Screener
10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is PTC Therapeutics, Inc. (PTCT) halal to invest in?
PTC Therapeutics, Inc. (PTCT) is rated Doubtful under AAOIFI Standard 21. It passes the business activity screen but one or more financial ratios are approaching (though not yet exceeding) the AAOIFI thresholds (30% for debt and interest deposits, 5% for prohibited income). Consult a qualified Islamic finance scholar for a personal ruling.
Why did PTC Therapeutics, Inc. get a B+ compliance rating?
PTC Therapeutics, Inc. (PTCT) received a grade of B+ (Good) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 4.4% (limit 30%); interest-bearing deposits of 29.9% (limit 30%); prohibited income of 0.00% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.
What could change PTC Therapeutics, Inc.'s Shariah verdict?
PTC Therapeutics, Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.
How often is PTC Therapeutics, Inc. re-screened for Shariah compliance?
PTC Therapeutics, Inc. (PTCT) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jun 17, 2026.

Screened according to AAOIFI Standard No. 21 路 For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.